April 14, 2026
Turner Pope Investments – indicative proposal for Ox-1 / DAT programmes
Capital Access Research
Capital Access Group releases a new research note outlining industry appetite for Orexin programmes following blockbuster transaction Read more
Filter by:
Date
Title
Download
April 14, 2026
Capital Access Group – Ox-1/DAT programmes – indicative proposal
April 13, 2026
Capital Access Group – Orexin M&A demonstrates industry appetite
March 23, 2026
Capital Access Group – Ox-1 Imminent start of final toxicology study
January 5, 2026
Capital Access – Ox-1 10kg toxicology study quantity achieved
December 18, 2025
Capital Access Group – DAT asset potential value highlighted
December 3, 2025
Turner Pope Investments, Research Note on Half-Year Results
December 3, 2025
Capital Access Group – Research Note on Half-Year Results
July 15, 2025
TheraCryf LTIP Rules 2025
July 9, 2025
Voting on AGM Resolutions
June 16, 2025
Notice of AGM 2025
June 3, 2025
Cavendish – Research Note on Full Year Results
June 3, 2025
Capital Access Group – Research Note on Full Year Results
June 3, 2025
Turner Pope Investments, Research Note on Full Year Results
May 12, 2025
Capital Access Group, Research – Pharmaron contract
May 12, 2025
Cavendish, Research – CDMO/CRO Selection
March 7, 2025
Voting on GM Resolution
February 19, 2025
Cavendish, Research
February 19, 2025
Tuner Pope Investments, Research
February 19, 2025
Capital Access Group, Research
February 19, 2025
Notice of General Meeting and Form of Proxy
July 18, 2024
Voting on AGM Resolutions
June 21, 2024
Notice of AGM and Proxy Form
May 20, 2024
Capital Access Group Analyst Research